Analytical Data
-
Gene name
FLK-1/VEGFR-2
-
简介
VEGFR-2 protein is an important tyrosine protein kinase receptor.As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis.It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization.VEGFR-2 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Biological Activity
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 this effect is 4.894 ng/mL in the presence of 5 ng/mL recombinant human VEGF165, corresponding to a specific activity is 2.043×105 units/mg. Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells.The ED50 for this effect is 4.894 ng/mL in the presence of 5 ng/mL recombinant human VEGF165, corresponding to a specific activity is 2.043×105 units/mg.
-
Alternative Names
Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; NYK; CD309
-
Species
Mouse
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35918
-
Expression Region
A20-E762
-
AA Sequence
ASVGLPGDFLHPPKLSTQKDILTILANTTLQITCRGQRDLDWLWPNAQRDSEERVLVTECGGGDSIFCKTLTIPRVVGNDTGAYKCSYRDVDIASTVYVYVRDYRSPFIASVSDQHGIVYITENKNKTVVIPCRGSISNLNVSLCARYPEKRFVPDGNRISWDSEIGFTLPSYMISYAGMVFCEAKINDETYQSIMYIVVVVGYRIYDVILSPPHEIELSAGEKLVLNCTARTELNVGLDFTWHSPPSKSHHKKIVNRDVKPFPGTVAKMFLSTLTIESVTKSDQGEYTCVASSGRMIKRNRTFVRVHTKPFIAFGSGMKSLVEATVGSQVRIPVKYLSYPAPDIKWYRNGRPIESNYTMIVGDELTIMEVTERDAGNYTVILTNPISMEKQSHMVSLVVNVPPQIGEKALISPMDSYQYGTMQTLTCTVYANPPLHHIQWYWQLEEACSYRPGQTSPYACKEWRHVEDFQGGNKIEVTKNQYALIEGKNKTVSTLVIQAANVSALYKCEAINKAGRGERVISFHVIRGPEITVQPAAQPTEQESVSLLCTADRNTFENLTWYKLGSQATSVHMGESLTPVCKNLDALWKLNGTMFSNSTNDILIVAFQNASLQDQGDYVCSAQDKKTKKRHCLVKQLIILERMAPMITGNLENQTTTIGETIEVTCPASGNPTPHITWFKDNETLVEDSGIVLRDGNRNLTIRRVRKEDGGLYTCQACNVLGCARAETLFIIEGAQEKTNLE
-
Protein Length
Extracellular Domain
-
Molecular Weight
138.21 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FLK-1, also known as VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2), is a key receptor in the vascular endothelial growth factor signaling pathway, primarily involved in angiogenesis and vascular permeability. The study of FLK-1/VEGFR-2 recombinant protein has gained significant attention due to its crucial role in both normal physiological processes and pathological conditions, such as cancer, where tumor growth and metastasis often rely on the formation of new blood vessels. Understanding the structure and function of FLK-1/VEGFR-2 can provide insights into its mechanism of action and its interaction with various ligands, such as VEGF-A. Moreover, the development of FLK-1/VEGFR-2 antagonists or inhibitors holds therapeutic potential, particularly in oncology, as targeting this pathway may prevent tumor angiogenesis and improve clinical outcomes. Additionally, research into FLK-1/VEGFR-2 can enhance our understanding of cardiovascular diseases, as dysregulation of this receptor can lead to various vascular disorders. Overall, the investigation of FLK-1/VEGFR-2 recombinant protein is pivotal in developing strategies for disease management and targeted therapies, making it a significant focus in biomedical research.
